Tag: SciRhom GmbH

October 18, 2024 Off

SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878

SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2 antibodies, today announced that the dosing of participants has commenced in the first clinical study evaluating the company’s most advanced development program SR-878.

April 11, 2022 Off

SciRhom Starts CMC Development of its First Drug Candidate for Clinical Development

By Author

SciRhom GmbH has nominated the anti-iRhom2 antibody it will advance into clinical development. For this antibody, the company has closed an agreement with a top-tier biopharmaceutical manufacturer for the CMC development.